Feb 10, 2020: Arctoris Ltd has announced a formal partnership with Molecule to address the ongoing crisis of innovation faced by drug discovery and development across industry and academia alike. “Arctoris helps researchers and biotechnology entrepreneurs to design and conduct advanced cellbased, molecular biology, and biochemical assays remotely through its fully automated drug discovery platform. Together with Molecule’s collaborative IP ownership network, which enables drug development stakeholders to collaborate and share ownership of the IP they work to develop, Arctoris and Molecule are positioned to take crucial steps to make drug discovery and production quicker, cheaper, less risk-prone and more competitive at all levels.
“Drug discovery researchers worldwide face enormous challenges posed by a wide-ranging lack of reproducibility and the limited ease of use of standardised, structured, high-quality data. By partnering with Molecule, we plan to make drug discovery and development more democratic, collaborative, and well-organized in the interest of bringing higher-quality therapeutics to the patients faster through the combination of robotics, AI and a distributed research platform,” said Martin-Immanuel Bittner, MD DPhil, Co-Founder and CEO of Arctoris.
Arctoris has planned and built a fully automated research facility based in Oxford (UK), where robotics perform a range of the most recurrent drug discovery assays for the researchers globally. The company offers the complete system in order to generate, analyse and visualize research data in a secure cloud environment, leveraging the benefits of the robotic experimentation, and providing full transparency, precision, and consistency in the preclinical R&D. Using the Arctoris platform, researchers worldwide can enjoy accelerated progress in their research, making discoveries faster, cheaper and more economically, while being liberated from manual work.
Jointly, Arctoris and Molecule will combine their technologies to create a modular pipeline for the distributed therapeutics development in the durability space and adjacent fields – a pipeline in which they will engage universities, patient advocacy groups, pharmaceutical and biotechnological companies, as well as investors”.
https://www.pharmiweb.com/press-release/2020-02-17/arctoris-announces-partnership-with-molecule-to-tackle-the-innovation-crisis-in-drug-discovery-and-development
